Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN5093-M114 in MET overexpressing advanced NSCLC
NCT04982224Phase 1Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2021
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of REGN5093-M114 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Dose Limiting Toxicities at 28 days, Treatment-Emergent Adverse Events at 2 years and 9 more. Started Nov 2021; status: terminated.
02
Drugs
REGN5093-M114
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04982224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04982224.